Randomised placebo-controlled trial of intravenous methylprednisolone in relapsed multiple sclerosis patients without the need for ranitidine cover

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46231139

Enrollment

Registered

2003-09-12

Start date

2003-07-24

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nervous System Diseases: Multiple sclerosis (MS) Nervous System Diseases Multiple sclerosis

Interventions

Sixty matched patients from those admitted for intravenous methylprednisolone treatment for their relapsed multiple sclerosis. Thirty will be randomised for an additional oral ranitidine cover, and th

Eligibility

Inclusion criteria

Inclusion criteria: Sixty matched patients from those admitted for intravenous methylprednisolone treatment for their relapsed multiple sclerosis.

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Between group differences in the absolute number of those who develop gastro-intestinal symptoms.	—

Secondary

Measure	Time frame
The number of those who develop gastro-intestinal symptoms who on clinical grounds require further investigation of their gastric mucosa for a possible ulcer or erosions in the 3, 6 and 12 months follow up durations.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026